CADENCE PHARMACEUTICALS

cadence-pharmaceuticals-logo

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.

#People #Financial #Website #More

CADENCE PHARMACEUTICALS

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2004-01-01

Address:
San Diego, California, United States

Country:
United States

Website Url:
http://www.cadencepharm.com

Total Employee:
251+

Status:
Closed

Contact:
8584361401

Email Addresses:
[email protected]

Total Funding:
86.6 M USD

Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Proofpoint Symantec.cloud



Current Advisors List

frank-torti_image

Frank Torti Investor @ Cadence Pharmaceuticals
Board_member

brian-atwood_image

Brian Atwood Board Member @ Cadence Pharmaceuticals
Board_member

jim-blair_image

Jim Blair Board Member @ Cadence Pharmaceuticals
Board_member

michael-eagle_image

Michael Eagle Member of the Board of Directors @ Cadence Pharmaceuticals
Board_member

olav-bergheim_image

Olav Bergheim Board of Directors @ Cadence Pharmaceuticals
Board_member

Current Employees Featured

ted-schroeder_image

Ted Schroeder
Ted Schroeder President & CEO @ Cadence Pharmaceuticals
President & CEO

Founder


ted-schroeder_image

Ted Schroeder

Stock Details


Company's stock symbol is NASDAQ:CADX

Investors List

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Post-IPO Equity - Cadence Pharmaceuticals

bay-city-capital_image

Bay City Capital

Bay City Capital investment in Post-IPO Equity - Cadence Pharmaceuticals

frazier-healthcare-ventures_image

Frazier Healthcare Partners

Frazier Healthcare Partners investment in Post-IPO Equity - Cadence Pharmaceuticals

venrock_image

Venrock

Venrock investment in Post-IPO Equity - Cadence Pharmaceuticals

domain-associates_image

Domain Associates

Domain Associates investment in Post-IPO Equity - Cadence Pharmaceuticals

t-rowe-price_image

T. Rowe Price

T. Rowe Price investment in Post-IPO Equity - Cadence Pharmaceuticals

versant-ventures_image

Versant Ventures

Versant Ventures investment in Post-IPO Equity - Cadence Pharmaceuticals

bay-city-capital_image

Bay City Capital

Bay City Capital investment in Post-IPO Equity - Cadence Pharmaceuticals

Official Site Inspections

http://www.cadencepharm.com

  • Host name: www.mallinckrodt.com
  • IP address: 146.214.96.246
  • Location: St Louis United States
  • Latitude: 38.6249
  • Longitude: -90.4496
  • Metro Code: 609
  • Timezone: America/Chicago
  • Postal: 63131

Loading ...

More informations about "Cadence Pharmaceuticals"

Cadence Pharmaceuticals Corporate Profile

At A Glance Address. 12481 High Bluff Dr., Ste. 200 San Diego, CA 92130 Phone: (858) 436-1400 Website: www.cadencepharm.com Product. OFIRMEV ® (acetaminophen ...See details»

Cadence Pharmaceuticals Corporate Profile - Anesthesiology News

At A Glance Address. 12481 High Bluff Dr., Ste. 200 San Diego, CA 92130 Phone: (858) 436-1400 Website: www.cadencepharm.com Product. OFIRMEV ® (acetaminophen ...See details»

Overview, News & Similar companies - ZoomInfo.com

View Cadence Pharmaceuticals (www.cadencepharm.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»

Cadence Pharmaceuticals - PitchBook

Cadence Pharmaceuticals General Information Description. Developer of proprietary product candidates principally for use in hospital settings. The …See details»

Cadence Pharmaceuticals - Products, Competitors, Financials, …

Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results. Oct 1, 2017. For the third quarter of 2011, net sales of Cadence's product, OFIRMEV® (acetaminophen) injection, …See details»

Company Cadence Pharmaceuticals, Inc. - MarketScreener.com

Apr 30, 2006 Cadence Pharmaceuticals, Inc.: Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq: | …See details»

Cadence acquired by Mallinckrodt - Versant Ventures

Cadence Pharmaceuticals is a biopharmaceutical company focused on commercializing products principally for use in the hospital setting. The company's product OFIRMEV® (acetaminophen …See details»

Cadence Pharmaceuticals, Inc. | Insights

Jul 25, 2018 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»

Cadence Pharmaceuticals Announces FDA Approval Of OFIRMEV ...

Nov 4, 2010 Cadence Pharmaceuticals is a biopharmaceutical company committed to in-licensing, developing and commercializing proprietary product candidates to improve the lives …See details»

Cadence Pharmaceuticals, Inc. Names Hazel Aker, J.D. Senior

Jun 5, 2007 CONTACT: William R. LaRue, SVP & Chief Financial Officer of CadencePharmaceuticals, Inc., +1-858-436-1400; or Media & Investor Relations,Susan Neath …See details»

Cadence Pharmaceuticals to Raise $86.6 Million in a Private …

Feb 17, 2009 The securities to be sold in this private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and will be sold in a …See details»

Cadence Pharmaceuticals, Inc. Completes Acquisition Of IV

Mar 29, 2006 SAN DIEGO, March 30 /PRNewswire/ -- Cadence Pharmaceuticals, Inc., a hospital-focused biopharmaceutical company, today announced that it has completed its …See details»

Cadence Pharmaceuticals Announces FDA Approval of …

Nov 2, 2010 Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV(TM) (acetaminophen) injection for the Management of Pain and Fever--First and Only Intravenous …See details»

Cadence Pharmaceuticals, Inc. Reports Mixed Results for Two Trials

Jan 11, 2008 Cadence expects to announce the results of a second study of Acetavance for the treatment of fever in adults, referred to as Study 303, later in the first quarter of 2008.See details»

Cadence Pharmaceuticals Reports Positive Outcome In OFIRMEV® …

Nov 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing...See details»

Cadence Pharmaceuticals Announces Strategic Plan to Secure …

Mar 6, 2013 For more information, please see the complete OFIRMEV Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com. About Cadence …See details»

Cadence Pharmaceuticals, Inc. Announces FDA Approval of

Nov 3, 2010 Cadence Pharmaceuticals is a biopharmaceutical company committed to in-licensing, developing and commercializing proprietary product candidates to improve the lives …See details»

Working at Cadence Pharmaceuticals - Glassdoor

See what employees say it's like to work at Cadence Pharmaceuticals. Salaries, reviews, and more - all posted by employees working at Cadence Pharmaceuticals.See details»

Cadence Pharmaceuticals Announces Strategic Plan to Secure …

SAN DIEGO, March 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and …See details»

linkstock.net © 2022. All rights reserved